PRILACTONE 80 mg COMPRIMIDOS PARA PERROS

Negara: Spanyol

Bahasa: Spanyol

Sumber: AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

Bahan aktif:

ESPIROLACTONA

Tersedia dari:

Ceva Sante Animale

Kode ATC:

QC03DA01

INN (Nama Internasional):

ESPIROLACTONA

Bentuk farmasi:

COMPRIMIDO

Komposisi:

Excipientes: TALCO, SORBITOL, LAURILSULFATO DE SODIO, MANITOL (E-421), AROMA DE CARNE ARTIFICIAL, ESTEARATO DE MAGNESIO, CELULOSA MICROCRISTALINA, POVIDONA

Rute administrasi :

VÍA ORAL

Jenis Resep:

Sujeto a prescripción veterinaria Desconocida

Kelompok Terapi:

Perros

Area terapi:

Espironolactona

Ringkasan produk:

PRILACTONE 80 mg COMPRIMIDOS PARA PERROS Caja con 30 comprimidos (3 blister) Autorizado No comercializado

Status otorisasi:

Autorizado

Tanggal Otorisasi:

2007-06-20

Selebaran informasi

[European Medicines Agency logo] European Medicines Agency - Science,
medicines, health [/]

Search for medicines ADVANCED DOCUMENT SEARCH
[/ema/index.jsp%3Fcurl=pages/document_library/landing/document_library_search.jsp]
MAIN NAVIGATION *
Home [/ema/index.jsp%3Fcurl=pages/home/Home_Page.jsp&mid=] *
Find medicine
[/ema/index.jsp%3Fcurl=pages/includes/medicines/medicines_landing_page.jsp&mid=] *
Human regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/human_medicines_regulatory.jsp&mid=] *
Veterinary regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/veterinary_medicines_regulatory.jsp&mid=] *
Committees
[/ema/index.jsp%3Fcurl=pages/about_us/general/general_content_000217.jsp&mid=] *
News & events
[/ema/index.jsp%3Fcurl=pages/news_and_events/landing/news_and_events.jsp&mid=] *
Partners & networks
[/ema/index.jsp%3Fcurl=pages/partners_and_networks/general/general_content_000212.jsp&mid=] *
About us
[/ema/index.jsp%3Fcurl=pages/about_us/document_listing/document_listing_000426.jsp&mid=] *
HUMAN MEDICINES
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124] *
EUROPEAN PUBLIC ASSESSMENT REPORTS
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125] *
EPARS: BACKGROUND AND CONTEXT
[/../index.jsp%3Fcurl=pages/medicines/general/general_content_000433.jsp&mid=WC0b01ac058067fa25] *
PATIENT SAFETY
[/../index.jsp%3Fcurl=pages/medicines/landing/pha_listing.jsp&mid=WC0b01ac058001d126] *
PENDING EC DECISIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/smop_search.jsp&mid=WC0b01ac058001d127] *
WITHDRAWN APPLICATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/wapp_search.jsp&mid=WC0b01ac058001d128] *
PAEDIATRICS
[/../index.jsp%3Fcurl=pages/medicines/landing/pip_search.jsp&mid=WC0b01ac058001d129] *
RARE DISEASE DESIGNATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/orphan_search.jsp&mid=WC0b01ac058001d12b] *
MEDICINES UNDER EVALUATION
[/../index.jsp%3Fcurl=pages/medicines/document_listing/document_listing_000349.jsp&mid=WC0b01ac0580508

Karakteristik produk

[European Medicines Agency logo] European Medicines Agency - Science,
medicines, health [/]

Search for medicines ADVANCED DOCUMENT SEARCH
[/ema/index.jsp%3Fcurl=pages/document_library/landing/document_library_search.jsp]
MAIN NAVIGATION *
Home [/ema/index.jsp%3Fcurl=pages/home/Home_Page.jsp&mid=] *
Find medicine
[/ema/index.jsp%3Fcurl=pages/includes/medicines/medicines_landing_page.jsp&mid=] *
Human regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/human_medicines_regulatory.jsp&mid=] *
Veterinary regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/veterinary_medicines_regulatory.jsp&mid=] *
Committees
[/ema/index.jsp%3Fcurl=pages/about_us/general/general_content_000217.jsp&mid=] *
News & events
[/ema/index.jsp%3Fcurl=pages/news_and_events/landing/news_and_events.jsp&mid=] *
Partners & networks
[/ema/index.jsp%3Fcurl=pages/partners_and_networks/general/general_content_000212.jsp&mid=] *
About us
[/ema/index.jsp%3Fcurl=pages/about_us/document_listing/document_listing_000426.jsp&mid=] *
HUMAN MEDICINES
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124] *
EUROPEAN PUBLIC ASSESSMENT REPORTS
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125] *
EPARS: BACKGROUND AND CONTEXT
[/../index.jsp%3Fcurl=pages/medicines/general/general_content_000433.jsp&mid=WC0b01ac058067fa25] *
PATIENT SAFETY
[/../index.jsp%3Fcurl=pages/medicines/landing/pha_listing.jsp&mid=WC0b01ac058001d126] *
PENDING EC DECISIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/smop_search.jsp&mid=WC0b01ac058001d127] *
WITHDRAWN APPLICATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/wapp_search.jsp&mid=WC0b01ac058001d128] *
PAEDIATRICS
[/../index.jsp%3Fcurl=pages/medicines/landing/pip_search.jsp&mid=WC0b01ac058001d129] *
RARE DISEASE DESIGNATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/orphan_search.jsp&mid=WC0b01ac058001d12b] *
MEDICINES UNDER EVALUATION
[/../index.jsp%3Fcurl=pages/medicines/document_listing/document_listing_000349.jsp&mid=WC0b01ac0580508